Ninety One UK 13F: Adds $371M to Illumina (ILMN) Stake

Ninety One UK dramatically expanded its investment in Illumina, Inc. (NasdaqGS: ILMN) during the period, according to a Form 13F filing with the SEC on October 15, 2026. This backward-looking report reflects holdings as of the end of the reporting period and may not represent the investor's current position today.

What Changed in Ninety One UK's Illumina Position

Ninety One UK boosted its stake in the genetic sequencing company by adding 1,356,397 shares. That represented a 37,919.9% increase over its prior holding of just 3,577 shares. The fund's total position reached 1,359,974 shares, with a reported value of $372,197,693.

Other Institutional Activity in Illumina

Other large institutional managers adjusted their positions in Illumina around the same reporting window. Blackrock Inc. grew its holdings by 167,411 shares, ending with 19,191,398 shares worth about $5,038,509,794. Capital World Investors reduced its stake by 124,398 shares, finishing with 15,425,298 shares valued at approximately $4,049,757,868. Vanguard Portfolio Management LLC trimmed its position by 196,522 shares to hold 6,627,157 shares worth about $1,739,893,855. Vanguard Capital Management LLC cut its holdings by 7,254 shares, leaving it with 6,587,534 shares valued at roughly $1,729,491,232. State Street Corporation added 77,797 shares to grow its stake to 6,507,288 shares worth about $1,708,423,447.

Illumina, Inc. Stock Down 2.0%

Illumina shares recently traded around $262.56 as of October 16, 2026. The stock sits roughly 12.9% above its 50-day moving average of $232.54 and about 55.4% above its 200-day moving average of $169.00. Over the past 52 weeks, the stock has traded as low as $94.00 and as high as $309.35.

Recent Earnings

Illumina reported trailing twelve-month revenue of $4,494,000,128 alongside trailing earnings of $5.39 per share. The company posted a net profit margin of 18.3% and a return on equity of 32.3%, while year-over-year revenue growth stood at 9.4%. The company's next quarterly earnings report is scheduled for October 29, 2026.

Dividend

Illumina currently pays no dividend, registering a dividend yield and payout ratio of 0.0%.

Insider Buying and Selling at Illumina, Inc.

Company insiders executed several transactions in the months leading up to the filing. Officer Christensen Jakob Wedel sold 1,033 shares on August 18, 2026, at an average price of $191.52 for a total value of $197,840. Director Keith A Meister made multiple sales, disposing of 679,574 shares on August 21, 2026, worth $145,556,398; 375,941 shares on August 27, 2026, worth $85,241,664; and 263,560 shares on September 4, 2026, worth $57,199,201.

Analysts Set New Price Targets

Wall Street analysts have updated their outlooks on Illumina through September and October 2026. On September 29, 2026, Leerink Partners maintained its Outperform rating while raising its price target to $300.00 from $220.00. Guggenheim maintained a Buy rating on October 1, 2026, lifting its target from $226.00 to $305.00. On October 5, 2026, RBC Capital maintained an Outperform rating and bumped its target to $310.00 from $230.00. Barclays maintained an Underweight rating on October 7, 2026, raising its target to $200.00 from $160.00. Finally, TD Cowen maintained a Hold rating on October 13, 2026, raising its target to $270.00 from $210.00. Across the broader analyst community, the stock carries a consensus buy recommendation and a mean price target of $241.05 based on 20 opinions.

About Illumina

Headquartered in San Diego, California, Illumina builds genetic and genomic analysis tools. The company creates sequencing and array-based systems used by researchers and clinicians in healthcare and diagnostics across global markets. Institutional filings like Ninety One UK's latest report offer a look at how large asset managers position themselves within the life sciences sector.

Bottom Line

Investors tracking Ninety One UK's strategy will want to monitor Illumina's upcoming earnings release on October 29, 2026, to gauge ongoing operational momentum. Because 13F reports look backward, subsequent filings will confirm whether the fund maintains this expanded stake moving forward.